UK cost agency backs Celgene bone marrow drug in change of tack

LONDON (Reuters) - Celgene's drug Revlimid should be an option on Britain's state health service for patients with serious bone marrow disorders and a specific chromosomal abnormality, the country's cost agency said on Wednesday.

Source: Reuters: Health - August 19, 2014 Category: Consumer Health News Tags: healthNews Source Type: news